ClinicalTrials.gg
CompletedNCT07123584Updated Aug 14, 2025

A Randomized Controlled Trial to Evaluate the Safety and Efficacy of an Oral Supplement in Supporting Vision and Eye Health

An interventional study of Eye Empower and Placebo in Dry Eye and Eye Fatigue, sponsored by Bio Nature Health. Completed at 1 site in United States. Open to participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by Bio Nature Health · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Nov 2024, registered Aug 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Study summary

This is a 4-week virtual randomized, triple-blinded, placebo-controlled clinical trial evaluating the safety and efficacy of Eye Empower, an oral supplement, in adults aged 45 or older experiencing dry eyes, irritation, and fatigue. Participants take 3 capsules daily and complete self-reported eye health questionnaires weekly.

02

Conditions studied

  • Dry Eye
  • Eye Fatigue

Keywords

  • Blurred Vision
  • Red or itchy eyes
03

In context

Dry Eye Syndromes

1,366 studies on the registry are indexed under Dry Eye Syndromes; 207 are open to participants now.

This study's enrollment of 60 is close to the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.

Browse Dry Eye Syndromes studies →

Lead sponsor

Bio Nature Health is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are male or female
  • Age 45 or over
  • Self-reported concerns about all three of the following symptoms over the last 4 weeks:

Dry eyes, Irritated eyes, Eye fatigue

- Self-reported concerns about any of the following symptoms over the last 4 weeks: Sensitivity to blue light, Blurred vision, far or near, Red or itchy eyes, Eye inflammation

  • Generally healthy - do not live with any uncontrolled chronic diseases
  • Willing to avoid using any new prescriptions, over-the-counter medications, supplements, and herbal remedies for the study that target eye health. This includes the use of new prescription eyeglasses or sunglasses
  • If taking oral over-the-counter supplements or herbal remedies targeted at eye health, has been consistently taking these for at least 3 months prior to starting the study, and is willing to maintain this routine for the study duration
  • Willing to maintain their current diet, sleep schedule, and activity level for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including cancer, liver, and mental health-related disorders
  • Anyone with diagnosed diabetes (Type I or Type II)
  • Planning to undergo any procedure related to their eye health during the study
  • Planning to undergo any surgeries or invasive treatments for the study duration
  • Has undergone any surgeries or invasive treatments in the last six months
  • History of any major illness in the last three months
  • Anyone currently taking or has taken a supplement with one or more of the active ingredients in the test product in the last month (e.g., turmeric)
  • Started any new medications or supplements that target eye health in the past 3 months
  • Anyone with known severe allergic reactions that may require the use of an EpiPen, including but not limited to a shellfish or a latex allergy
  • Women who are pregnant, breastfeeding, or trying to conceive currently and for the duration of the study
  • Anyone on a medication or herbal supplement that can impact the blood (e.g., blood thinner, anticoagulant, etc.) including but not limited to:

Coumadin (Warfarin) Aspirin Plavix (Clopidogrel)

  • Anyone who does not consume animal products for religious and/or personal reasons
  • Unwilling to follow the study protocol
  • Anyone who has undergone any surgeries or invasive treatments in the last three months or has any planned during the study period
  • Anyone with a history of substance abuse
  • Anyone who uses illicit drugs, including cannabis
  • Anyone who drinks heavily (i.e., 8 or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Eye Empower supplement

    Dietary Supplement: Eye Empower

  • Placebo comparator
    Placebo

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementEye Empower

    A multi-ingredient oral supplement formulated to support eye health. Daily dose (3 capsules).

  • Dietary supplementPlacebo

    Identical gelatin capsules filled with inert rice flour, administered in the same dosage (3 capsules daily).

06

What researchers measure

Primary outcomes

  1. Change in Eye Health Symptoms (Dryness, Irritation, Fatigue, and Visual Acuity)

    Assessment of changes in eye dryness, irritation, fatigue, and visual acuity using a self-reported questionnaire administered weekly.

    Time frame: Baseline, Week 1, Week 2, Week 3, Week 4

Secondary outcomes

  1. Change in Perceived Overall Eye Health

    Evaluation of participants' self-reported overall eye health using a standardized questionnaire administered weekly throughout the study.

    Time frame: Baseline, Week 1, Week 2, Week 3, Week 4

07

Study locations

1 site
  • Citruslabs
    Las Vegas, Nevada 89118, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Dec 2024, 1 month.

Of 113 industry-sponsored interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 1 month is below that.

Counting every sponsor, half of 312 studies reached it within 10 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2025
First posted
Aug 14, 2025
StartActual
Nov 6, 2024
Primary completionActual
Dec 30, 2024
CompletionActual
Dec 30, 2024
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07123584
Lead sponsor
Bio Nature Health
Collaborators
Citruslabs
Responsible party
Sponsor
First posted
Aug 14, 2025
Start date
Nov 6, 2024
Primary completion
Dec 30, 2024
Completion
Dec 30, 2024
Last update
Aug 14, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion